Small intestinal bacterial overgrowth (SIBO) is a condition where bacteria that normally reside in the colon colonize the small intestine, potentially causing bloating, pain, and malabsorption. While methane and hydrogen SIBO are well known, a less understood variant involves hydrogen sulfide (H₂S) gas. H₂S SIBO is thought to arise when sulfate-reducing bacteria (SRB) overgrow in the small bowel, producing H₂S that may damage the gut lining and trigger symptoms. This article explores how H₂S SIBO develops, drawing on the latest research into gut microbiota, intestinal motility, and barrier function.
Key takeaways
H₂S SIBO is a proposed subtype of SIBO driven by sulfate-reducing bacteria that produce hydrogen sulfide gas.
Development is linked to impaired gut motility, dietary sulfur intake, and gut dysbiosis [4,5,7].
Excess H₂S may damage the gut barrier, contributing to leaky gut and inflammation [2,3].
Current breath tests do not reliably measure H₂S, making diagnosis challenging [4,9].
Management focuses on diet, probiotics, and addressing underlying motility issues, but more research is needed.
What Is SIBO and Why Does H₂S Matter?
Small intestinal bacterial overgrowth (SIBO) is defined by an abnormal increase in the number and/or type of bacteria in the small intestine. The SIBO hypothesis, though still debated, suggests that these bacteria can produce symptoms even without malabsorption [4]. Traditionally, breath tests measure hydrogen and methane, but hydrogen sulfide (H₂S) is another gas produced by certain gut microbes, especially sulfate-reducing bacteria [7]. H₂S at low levels may have signaling roles, but excessive production can be toxic, potentially contributing to intestinal inflammation and leaky gut [2, 3]. Understanding H₂S SIBO requires looking at how these bacteria gain a foothold in the small intestine.
Key Factors That Drive H₂S SIBO Development
Impaired gut motility: The small intestine normally clears bacteria through peristalsis. When motility is slowed—due to conditions like scleroderma, diabetes, or post-surgical changes—bacteria can accumulate [4, 8]. This stasis creates an environment where SRB can thrive.
Dysbiosis and diet: A shift in the gut microbiome composition, often called dysbiosis, can favor SRB overgrowth. Diets high in sulfur-containing foods (e.g., red meat, eggs, cruciferous vegetables) or the use of certain medications may promote H₂S production [1, 5]. The balance of gut microbes is influenced by diet, lifestyle, and host factors [1].
Intestinal permeability (leaky gut): H₂S can damage the intestinal epithelial barrier, increasing permeability. This allows bacterial products to enter the bloodstream, triggering systemic inflammation [2, 3]. A leaky gut may further perpetuate dysbiosis and SIBO, creating a vicious cycle.
The Role of Hydrogen Sulfide in Gut Inflammation
Hydrogen sulfide is a potent gas that, in excess, can inhibit mitochondrial respiration and disrupt the gut barrier. Studies show that H₂S production by infant gut microbiota varies with diet and can reach levels that may be harmful [7]. In the context of SIBO, H₂S may contribute to intestinal inflammation, which is linked to conditions like irritable bowel syndrome (IBS) and even Parkinson's disease via the gut-brain axis [3, 4, 6]. The inflammatory response can further impair motility and barrier function, reinforcing bacterial overgrowth.
Diagnosing H₂S SIBO: Challenges and Breath Testing
Breath testing is commonly used to diagnose SIBO by measuring hydrogen and methane after a sugar challenge. However, H₂S is not routinely measured in clinical breath tests, and current methods have limitations [4, 9]. The SIBO hypothesis itself remains unproven, and breath tests are not validated for H₂S detection [4]. Some researchers are exploring alternative approaches, but as of now, H₂S SIBO is not a standard diagnosis. Clinicians often rely on symptom patterns and response to dietary changes or antibiotics.
Implications for Management and Future Research
If H₂S SIBO is suspected, management may include a low-sulfur diet, probiotics that compete with SRB, and possibly targeted antibiotics. However, evidence is limited. The gut microbiome is highly individual, and what works for one person may not for another [1]. Future research should focus on validating breath tests for H₂S, understanding the specific microbial strains involved, and exploring how diet and prebiotics can modulate H₂S production [5, 7]. Until then, a cautious, evidence-based approach is recommended.
Frequently asked questions
What causes hydrogen sulfide SIBO?
H₂S SIBO is thought to develop when sulfate-reducing bacteria overgrow in the small intestine, often due to impaired gut motility, dietary factors (high sulfur intake), and gut dysbiosis [4, 5, 7].
How is H₂S SIBO diagnosed?
Currently, there is no standard breath test for H₂S. Diagnosis is usually based on symptoms and ruling out other conditions. Some labs offer experimental H₂S breath testing, but it is not validated [4, 9].
Can H₂S SIBO cause leaky gut?
Excess hydrogen sulfide can damage the intestinal lining, increasing permeability (leaky gut), which may allow toxins to enter the bloodstream and trigger inflammation [2, 3].
What foods should I avoid if I have H₂S SIBO?
A low-sulfur diet—limiting red meat, eggs, cruciferous vegetables, and high-sulfur preservatives—may help reduce H₂S production, but individual responses vary [1, 5].
Is H₂S SIBO the same as hydrogen or methane SIBO?
No. Each type is associated with different gas-producing bacteria. H₂S SIBO involves sulfate-reducing bacteria, while hydrogen SIBO involves fermenters and methane SIBO involves archaea [4, 7].
References
What defines a healthy gut microbiome? — Van Hul M et al., 2024, Gut
Leaky Gut and the Ingredients That Help Treat It: A Review — Aleman RS et al., 2023, Molecules (Basel, Switzerland)
Intestinal Inflammation and Parkinson's Disease — Li Y et al., 2021, Aging and disease
Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS) — Kashyap P et al., 2024, Neurogastroenterology and motility
Implications of Gut Microbiota in Complex Human Diseases — Yu D et al., 2021, International journal of molecular sciences
The Oral-Gut Microbiome-Brain Axis in Cognition — Adil NA et al., 2025, Microorganisms
Evolution of Intestinal Gases and Fecal Short-Chain Fatty Acids Produced <i>in vitro</i> by Preterm Infant Gut Microbiota During the First 4 Weeks of Life — Wang X et al., 2021, Frontiers in pediatrics
Recent advances in small bowel diseases: Part II — Thomson AB et al., 2012, World journal of gastroenterology
Overview of Breath Testing in Clinical Practice in North America — Nichols BL et al., 2021, JPGN reports
Controlling toxic and harmful gas in blasting with an inhibitor — Yi H et al., 2023, PloS one
Microbial allies in skin trauma recovery: from immune modulation to engineered probiotic therapeutics — Wang AYL et al., 2026, Burns & trauma